Exopharm (ASX:EX1) is at the forefront of transformative medicines that harness the superpower of exosomes or extracellular vesicles (EVs) and is pursuing a pipeline-driven platform strategy.
Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and surface engineered to target selected cell-types and tissue types, improving the safety-profile of modern APIs and optimizing clinical outcomes.
Exosome delivery of DNA and other gene therapies into the nucleus of the patient’s cells can improve treatment of inherited medical conditions. Exosomes can also be used to deliver small molecule drugs, mRNA and other modern medicines.
Exopharm technology platforms – LEAP manufacturing technology, LOAD API loading technology.
Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and surface engineered to target selected cell-types and tissue types, improving the safety-profile of modern APIs and optimizing clinical outcomes.
Exosome delivery of DNA and other gene therapies into the nucleus of the patient’s cells can improve treatment of inherited medical conditions. Exosomes can also be used to deliver small molecule drugs, mRNA and other modern medicines.
Exopharm technology platforms – LEAP manufacturing technology, LOAD API loading technology.
Ticker:
EX1
Exchange:
ASX:
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Stealth
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3 platforms - LEAP, EVPS, LOAD
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
